Literature DB >> 6360693

Hypotensive effects of diltiazem to normals and essential hypertensives.

K Aoki, K Sato, S Kondo, M Yamamoto.   

Abstract

The hypotensive effect of acute and longterm, intravenous and oral administration of the calcium antagonist, diltiazem, was investigated in 8 normotensive volunteers and 55 patients with essential hypertension. Diltiazem i.v. infusion of 45 mg/h (0.5 mg/min, then 1.0 mg/min, each for 30 min rapidly decreased both blood pressure (BP) from 164 +/- 22/98 +/- 8 to 144 +/- 15/86 +/- 9 mmHg (mean +/- SD) and total peripheral resistance from 32.6 +/- 8.4 to 25.3 +/- 5.4 mmHg/l/min (p less than 0.001), and increased stroke volume from 58.2 +/- 9.5 to 64.2 +/- 8.6 ml/beat (p less than 0.05). It altered neither heart rate nor cardiac output in the hypertensives (n = 10). Oral diltiazem 60 mg rapidly decreased BP from 155 +/- 10/103 +/- 6 to 142 +/- 12/90 +/- 8 mmHg after 3 hours (p less than 0.01/p less than 0.001) in hypertensives (n = 8), but not in normotensives (n = 8). Diltiazem 90 mg p.o. decreased BP from 157 +/- 15/102 +/- 9 to 129 +/- 13/83 +/- 8 mmHg (p less than 0.01) in hypertensives (n = 15), and reduced the heart rate from 71 +/- 8 to 65 +/- 8 beats/min (p less than 0.01). The drug did not change plasma renin activity either in normotensives or hypertensives. The fall in diastolic BP was correlated with the plasma diltiazem concentration (r = 0.910, n = 6, p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6360693     DOI: 10.1007/bf00542114

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

Review 1.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

2.  Therapeutic implications of slow-channel blockade in cardiocirculatory disorders.

Authors:  G Ellrodt; C Y Chew; B N Singh
Journal:  Circulation       Date:  1980-10       Impact factor: 29.690

3.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

4.  Acute and long-term hypotensive effects and plasma concentrations of nifedipine in patients with essential hypertension.

Authors:  K Aoki; K Sato; Y Kawaguchi; M Yamamoto
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients.

Authors:  K Aoki; T Yoshida; S Kato; K Tazumi; I Sato
Journal:  Jpn Heart J       Date:  1976-07

Review 6.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

7.  Antihypertensive effect of (4-2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, Bay-a 1040), a new coronary dilator.

Authors:  M Murakami; E Murakami; N Takekoshi; M Tsuchiya; T Kin
Journal:  Jpn Heart J       Date:  1972-03

8.  Enhanced vasodilatation in essential hypertension by calcium channel blockade with verapamil.

Authors:  U L Hulthén; P Bolli; F W Amann; W Kiowski; F R Bühler
Journal:  Hypertension       Date:  1982 May-Jun       Impact factor: 10.190

9.  Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms.

Authors:  R W Millard; D A Lathrop; G Grupp; M Ashraf; I L Grupp; A Schwartz
Journal:  Am J Cardiol       Date:  1982-02-18       Impact factor: 2.778

10.  Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review.

Authors:  L B Mitchell; J S Schroeder; J W Mason
Journal:  Am J Cardiol       Date:  1982-02-18       Impact factor: 2.778

View more
  7 in total

1.  Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers.

Authors:  A Gordin; P Pohto; S Sundberg; S Nykänen; H Haataja; P Männistö
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Effect of the calcium antagonist nilvadipine on haemodynamics at rest and during cold stimulation in essential hypertension.

Authors:  T Takabatake; Y Yamamoto; S Nakamura; N Hashimoto; S Satoh; Y Yamada; H Ohta; N Hattori
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Effects of felodipine and metoprolol on blood pressure, plasma renin, angiotensin II, aldosterone and catecholamines in hypertensive patients.

Authors:  P Lijnen; R Fagard; J Staessen; E Moerman; A De Schaepdryver; A Amery
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Diltiazem as augmentation therapy in patients with treatment-resistant bipolar disorder: a retrospective study.

Authors:  P H Silverstone; L Birkett
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

Review 5.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

6.  Twenty-four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension.

Authors:  A G Dupont; J M Coupez; P Jensen; R Coupez-Lopinot; D F Schoors; P Hermanns; M Nicolas
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

7.  Retrospective analysis of risk factors of hypotensive bradycardic events during shoulder arthroscopic surgery under interscalene blockade in the sitting position.

Authors:  Taeha Ryu; Baek Jin Kim; Seong Jun Woo; So Young Lee; Jung A Lim; Sang Gyu Kwak; Woon Seok Roh
Journal:  Korean J Anesthesiol       Date:  2020-03-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.